Bio-Safety Level 3 Core

The Ragon BSL3 core provides biosafety level-3 laboratory space, training, and consultation for academic and industrial researchers working with risk group-3 pathogens, such as M. tuberculosis, SARS-CoV-2, Chikungunya virus, West Nile virus, Powassan virus, Japanese Encephalitis virus, Dabie bandavirus, Heartland virus and Bhanja virus. 

Researchers are required to complete 30 hours of BSL3 specific training to become certified BSL3 core users. Training covers special facility containment, BSL-3 specific PPE, and safety regulations specific to risk group-3 pathogens.

Director

Amy Barczak

Scientific Director

Contact

Julie Boucau

Co-Director

Yong (Mike) Xie

Director

Services and Pricing

The Ragon BSL3 is one of the largest (2200 square feet) and most heavily used BSL3 facility in the region, with an excellent safety track record. The lab is equipped with dedicated 12-color high-speed cell sorter and microscopy equipment, as well as cell culture hoods and standard cell and molecular biology resources.

Learn More

Selected Publications

Virologic features of SARS-CoV-2 infection in children

Lael M Yonker, Julie Boucau, James Regan, Manish C Choudhary, Madeleine D Burns, Nicola Young, Eva J Farkas, Jameson Davis, Peter P Moschovis, T Bernard Kinane, Alessio Fasano, Anne M Neilan, Jonathan Z Li, Amy K Barczak

MedRxiv PubMed

SARS-CoV-2 Persistence and Evolution in an Immunocompromised Host

Choi B, Choudary M, Regan J, Sparks JA, Padera RF Jr, Qiu X, Solomon I, Kuo HH, Boucau J, Bowman KA, Das Adhikari U, Winkler ML, Mueller AM, Hsu TY, Desjardins M, Baden L, Chan B, Walker BD, Lichterfeld MD, Brigl M, Kwon DK, Kanjilal S, Richardson ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha G, Seaman M, Cernadas M, Li J

New England Journal of Medicine 2020 Dec 3; 383(23) PubMed

Determining the Incidence of Asymptomatic SARS-CoV-2 among Early Recipients of COVID-19 Vaccines: A Prospective Cohort Study of Healthcare Workers before, during and after Vaccination [DISCOVER-COVID-19]

North CM, Barczak AK, Goldstein RH, Healy B, Finkelstein DM, Ding D, Kim J, Boucau J, Shaw B, Gilbert B, Vyas T, Reynolds Z, Regan J, Flynn J, Choudary M, Vyas J, Laskowski K, Dighe A, Lemieux J, Li JZ, Baden LR, Siedner MJ, Woolley AE, Sacks CA

Clinical Infectious Disease 2021 Aug 7 PubMed